Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $165.00 by Analysts at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target cut by stock analysts at JPMorgan Chase & Co. from $174.00 to $165.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 38.08% from the company's previous close.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald dropped their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an "overweight" rating on the stock in a research report on Wednesday. Morgan Stanley raised their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an "equal weight" rating in a research report on Thursday, May 16th. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group raised their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a report on Tuesday, August 13th. Finally, Evercore ISI upgraded shares of Ascendis Pharma A/S to a "strong-buy" rating in a report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $188.09.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded down $15.18 during trading hours on Wednesday, reaching $119.50. The company's stock had a trading volume of 3,189,468 shares, compared to its average volume of 389,701. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00. The company has a market capitalization of $6.96 billion, a P/E ratio of -12.43 and a beta of 0.63. The stock's fifty day simple moving average is $135.32 and its two-hundred day simple moving average is $138.73.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ASND. GAMMA Investing LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $25,000. Gilbert & Cook Inc. increased its position in shares of Ascendis Pharma A/S by 8.4% in the fourth quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company's stock worth $357,000 after purchasing an additional 220 shares during the last quarter. Jump Financial LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter worth approximately $1,681,000. Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 20.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company's stock valued at $191,346,000 after acquiring an additional 254,749 shares during the last quarter. Finally, First Turn Management LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at approximately $19,092,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.